Skip to main content

REVIEW article

Front. Virol.
Sec. Viral Diversification and Evolution
Volume 4 - 2024 | doi: 10.3389/fviro.2024.1399993
This article is part of the Research Topic Impact of the SARS-CoV-2 pandemic on the evolution and epidemiology of other viruses View all 3 articles

An overview of SARS-CoV-2 viral proteins with relevance to improved diagnostic and therapeutic platforms

Provisionally accepted
Christopher Chung Christopher Chung 1Pratiba Irudayaraj Pratiba Irudayaraj 1Emran Lallow Emran Lallow 1Ziyang Xu Ziyang Xu 2Ziyang Xu Ziyang Xu 2Young Park Young Park 1Luis Montaner Luis Montaner 3Sagar B. Kudchodkar Sagar B. Kudchodkar 1Alagarsamy Srinivasan Alagarsamy Srinivasan 4Kar Muthumani Kar Muthumani 1*
  • 1 GeneOne Life Science, Inc., Seoul, Republic of Korea
  • 2 Langone Medical Center, New York University, New York City, New York, United States
  • 3 The Wistar Institute, Philadelphia, Pennsylvania, United States
  • 4 NanoBio Diagnostics,, West Chester, PA-19382, United States

The final, formatted version of the article will be published soon.

    In the past 25 years, the world has witnessed outbreaks of illnesses in humans from three different coronaviruses. Both the SARS-CoV outbreak of 2003 and the MERS-CoV outbreak of 2013 resulted in overall low fatalities in part due to inefficient human-to-human spread of each virus. In contrast, SARS-CoV-2, which emerged in 2019, was highly efficient at human-to-human spread and caused a global pandemic resulting in millions of casualties. Zoonotic transmission of viruses, including the three coronaviruses, poses an ongoing threat that cannot be ignored. In this review, we have focused on the diagnostics and therapeutics fronts using SARS-CoV-2 as a model. Specifically, we have selected proteins associated with the virus particles as targets and discussed various platform technologies. These insights hold the potential to inform the development of more effective therapeutics and vaccines not only for SARS-CoV-2 but also for future viral pandemics, thus contributing to global health on a broader scale.

    Keywords: SARS-CoV-2 Viral Structural Proteins, Infections and Variants, Clinical diagnostics, Therapeutics, vaccine development

    Received: 12 Mar 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Chung, Irudayaraj, Lallow, Xu, Xu, Park, Montaner, Kudchodkar, Srinivasan and Muthumani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Kar Muthumani, GeneOne Life Science, Inc., Seoul, 06060, Republic of Korea

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.